2026-08-05T09:54:36Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/168372025-04-01T09:07:07Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16968
Repisalud
author
Fontán-Vela, Mario
author
Hernando Sebastian, Victoria
author
Olmedo, Carmen
author
Coma, Ermengol
author
Martínez, Montse
author
Moreno-Perez, David
author
Lorusso, Nicola
author
Vázquez Torres, María
author
Barbas del Buey, José Francisco
author
Roig-Sena, Javier
author
Pastor, Eliseo
author
Galmés Truyols, Antònia
author
Artigues Serra, Francisca
author
Sancho Martínez, Rosa María
author
Latasa Zamalloa, Pello
author
Pérez Martínez, Olaia
author
Vázquez Estepa, Ana
author
García Rojas, Amós José
author
Barreno Estévez, Ana Isabel
author
Sánchez-Migallón Naranjo, Alonso
author
Pérez Martín, Jaime Jesús
author
Peces Jiménez, Pilar
author
Morales Romero, Raquel
author
Castilla, Jesús
author
Garcia-Cenoz, Manuel
author
Huerta Huerta, Marta
author
Boone, An Lieve Dirk
author
Macías Ortiz, María José
author
Álvarez Río, Virginia
author
Rodríguez Recio, María Jesús
author
Merino Díaz, María
author
Berradre-Sáenz, Belén
author
Villegas-Moreno, María Teresa
author
Limia, Aurora
author
Diaz Franco, Asuncion
author
Monge Corella, Susana
author
Spanish MPOX vaccine effectiveness study group
author
Jarrin Vera, Inmaculada
2023-12-18T18:10:01Z
2023-12-18T18:10:01Z
2024
Clin Infect Dis. 2024 Feb 17;78(2):476-483.
10.1093/cid/ciad645
1537-6591
1058-4838
Clinical Infectious Diseases
37864849
http://hdl.handle.net/20.500.12105/16837
Background: With over 7,500 cases notified since April 2022, Spain has experienced the highest incidence of mpox in Europe. From July 12th onwards, the Modified Vaccinia Ankara-Bavaria Nordic (MVA-BN) smallpox vaccine was offered as pre-exposure prophylaxis for individuals at high-risk of mpox, including those receiving pre-exposure prophylaxis for HIV (HIV-PrEP). Our aim was to assess the effectiveness of one dose of MVA-BN vaccine as pre-exposure against mpox virus (MPXV) infection in persons on HIV-PrEP. Methods: We conducted a national retrospective cohort study between July 12 and December 12, 2022. Individuals ≥18 years, receiving HIV-PrEP as of July 12 and with no previous MPXV infection or vaccination were eligible. Each day, we matched individuals receiving a first dose of MVA-BN vaccine and unvaccinated controls of the same age group and region. We used a Kaplan-Meier estimator and calculate risk ratios (RR) and vaccine effectiveness (VE = 1-RR). Results: We included 5,660 matched pairs, with a median follow-up of 62 days (interquartile range 24-97). Mpox cumulative incidence was 5.6 per 1,000 (25 cases) in unvaccinated and 3.5 per 1,000 (18 cases) in vaccinated. No effect was found during days 0-6 post-vaccination (VE -38.3; 95% confidence interval (95%CI): -332.7; 46.4), but VE was 65% in ≥7 days (95%CI 22.9; 88.0) and 79% in ≥14 days (95%CI 33.3; 100.0) post-vaccination. Conclusions: One dose of MVA-BN vaccine offered protection against mpox in a most-at-risk population shortly after the vaccination. Further studies need to assess the VE of a second dose and the duration of protection over time.
eng
mpox
Monkeypox
Vaccine effectiveness
MVA-BN vaccine
Pre-exposure prophylaxis
Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study
research article
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
URL
https://repisalud.isciii.es/bitstreams/56799bf0-aa65-46bb-b3a8-5f7d609e3f8d/download
File
MD5
62dc3e24a582e14f15c1fe1593092b9d
527123
application/pdf
EffectivenessModifiedVacciniaAnkara-BavariaNordic_2024.pdf
URL
https://repisalud.isciii.es/bitstreams/a710b93a-bc93-4855-b11c-5f8b3b2f5937/download
File
MD5
ba81f54c6d8832c316c8daad85174efe
842952
application/pdf
Supplementary_EffectivenessMVA-BN_Vaccination_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/c0071034-1455-4026-bd1c-5381cf3c70fb/download
File
MD5
3c5de633fa35f7db61331fe0d05cb910
44193
text/plain
EffectivenessMVA-BN_Vaccination_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/79edfb29-da8d-4cf9-8fed-8235400702e4/download
File
MD5
e7170f7cf2fc02abeff12aec00d9dcf3
6551
text/plain
Supplementary_EffectivenessMVA-BN_Vaccination_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/b24e833d-d98c-4a80-ba1c-594d48ab2e8e/download
File
MD5
adb899089c50e387129c9500295f0588
40819
text/plain
EffectivenessModifiedVacciniaAnkara-BavariaNordic_2024.pdf.txt